US Grants Zero Tariff Status for Speciality Drugs and Ingredients From India

A question can test understanding of tariff classification mechanisms—specifically ad valorem tariffs and their removal as a trade barrier—and India's pharmaceutical export profile to the United States. The decision to grant zero-tariff status to specialty drugs and active pharmaceutical ingredients from India and 19 other nations represents a specific trade policy outcome testable in international trade or bilateral commerce contexts.

No specific implementation concern is stated in the supplied report.

The elimination of ad valorem tariffs on Indian specialty pharmaceutical products directly reduces export costs and enhances competitiveness of Indian pharma manufacturers in the US market, a major destination for Indian pharmaceutical exports. This tariff reform facilitates trade in critical pharmaceutical inputs and finished products.

• US has established zero-tariff regime on select specialty drugs and active pharmaceutical ingredients from India and 19 other nations • Ad valorem tariffs (calculated as fixed percentage of import value) have been removed on these products • No third verified fact is provided.